Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3268694 | 0.90 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| Fumaric Acid SCHEMBL3268699 | 0.90 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5776335 | 0.89 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13307095 | 0.80 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6186637 | 0.79 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3268410 | 0.77 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5776339 | 0.76 | HTT (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6186913 | 0.75 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5994946 | 0.75 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5996491 | 0.75 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735302-B1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1735302-B1 | 4-AMINO-PIPERIDINE DERIVATIVES AS MONOAMINE UPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| US-7521462-B2 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521462-B2 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521462-B2 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093526-A1 | 4-Amino-piperidine derivatives as monoamine uptake inhibitors | SLC18A2, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A4 4/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.